Mr. Yevgeniy Meshcherekov is a seasoned financial executive and Chartered Professional Accountant, bringing over 20 years of post-designation experience across public practice, private enterprise, and ...

SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...

Le Document d’Enregistrement Universel 2024 de GENFIT comprend notamment : Le rapport du conseil d’administration sur le gouvernement d’entreprise, Les rapports des contrôleurs légaux des comptes sur ...

GENFIT’s 2024 Universal Registration Document includes, in particular : The Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements, The table ...

This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo ,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “ We could not ...

About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...

Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à disposition du public et déposé auprès de ...

DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...

Commercial Progress: The first full quarter of Attruby net product revenue was $36.7 million. As of April 25, 2025, 2,072 unique patient prescriptions for Attruby have been written by 756 unique ...

The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target ...